Phathom Pharmaceuticals, Inc.
NASDAQ: PHAT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven L. Basta
- Employees
- 427
- Headquarters
- Florham Park, United States
- IPO year
- 2019
- Market cap
- $846.2M
- Website
- https://www.phathompharma.com
Loading PHAT…
Loading profile data…Frequently asked questions about PHAT
What does Phathom Pharmaceuticals, Inc. (PHAT) do?
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom h...
Where does PHAT trade?
Phathom Pharmaceuticals, Inc. (PHAT) trades on the NASDAQ Global Select.
What sector is PHAT in?
Phathom Pharmaceuticals, Inc. (PHAT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Phathom Pharmaceuticals, Inc.?
Steven L. Basta is the chief executive officer of Phathom Pharmaceuticals, Inc. (PHAT).
Where is Phathom Pharmaceuticals, Inc. headquartered?
Phathom Pharmaceuticals, Inc. is headquartered in United States.
Does PHAT pay a dividend?
Phathom Pharmaceuticals, Inc. (PHAT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PHAT go public?
Phathom Pharmaceuticals, Inc. (PHAT) completed its initial public offering in 2019.